SLC5A2 and diabetic kidney disease: Medications such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), as well as sodium glucose cotransporter-2 inhibitors (SGLT-2i) and nonsteroid aldosterone receptor antagonists (NS-MRAs) have been approved for the purpose of slowing the progression of DKD [12].